TY - JOUR
T1 - THE EFFICACY OF MARINE NATURAL PRODUCTS AGAINST PLASMODIUM FALCIPARUM
AU - Goto, Yukihiro
AU - Kamihira, Rie
AU - Nakao, Yoichi
AU - Nonaka, Motohiro
AU - Takano, Ryo
AU - Xuan, Xuenan
AU - Kato, Kentaro
N1 - Funding Information:
From the Divisions of Cardiology and Nephrology. Department of Medicine. Duke University Medical Center, Durham. North Carolina. This work was supported by a grant from Squibb Diagnostics Incorporated. Princeton. New Jersey. Additional support was given by Research Grant HL-36587 from the National Heart. Lung. and Blood Institute. Bethesda. Maryland: Research Grant HS-05635 from The Agency for Health Care Policy and Research. Public Health Service. Department of Health and Human Services. Rockville. Maryland and grants from the Robert Wood Johnson Foundation. Princeton.
Publisher Copyright:
© American Society of Parasitologists 2021.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Malaria remains one of the most important infectious diseases in the world. In 2017 alone, approximately 219 million people were infected with malaria, and 435,000 people died of this disease. Plasmodium falciparum, which causes falciparum malaria, is becoming resistant to artemisinin (ART) in Southeast Asia; therefore, new antimalarial drugs are urgently needed. Some excellent antimalarial drugs, such as quinine and ART, were originally obtained from plants. Hence, we analyzed the antimalarial effects of marine natural products to find new antimalarial agents. We used a malaria growth inhibition assay to determine the antimalarial ability and half-maximal inhibitory concentration (IC50) values of the marine organism-derived compounds. Three compounds (kapakahine A, kapakahine B, and kulolide-1) showed antimalarial effects, and one (kapakahine F) showed selective antimalarial effects on the Dd2 clone. Although the IC50 values obtained for these compounds were greater than that of ART, their potency against P. falciparum is sufficient to warrant further investigation of these compounds as possible drug leads.
AB - Malaria remains one of the most important infectious diseases in the world. In 2017 alone, approximately 219 million people were infected with malaria, and 435,000 people died of this disease. Plasmodium falciparum, which causes falciparum malaria, is becoming resistant to artemisinin (ART) in Southeast Asia; therefore, new antimalarial drugs are urgently needed. Some excellent antimalarial drugs, such as quinine and ART, were originally obtained from plants. Hence, we analyzed the antimalarial effects of marine natural products to find new antimalarial agents. We used a malaria growth inhibition assay to determine the antimalarial ability and half-maximal inhibitory concentration (IC50) values of the marine organism-derived compounds. Three compounds (kapakahine A, kapakahine B, and kulolide-1) showed antimalarial effects, and one (kapakahine F) showed selective antimalarial effects on the Dd2 clone. Although the IC50 values obtained for these compounds were greater than that of ART, their potency against P. falciparum is sufficient to warrant further investigation of these compounds as possible drug leads.
KW - Antimalarial drugs
KW - Drug effects
KW - Marine organism–derived compounds
KW - Plasmodium falciparum
UR - http://www.scopus.com/inward/record.url?scp=85104343624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104343624&partnerID=8YFLogxK
U2 - 10.1645/20-93
DO - 10.1645/20-93
M3 - Article
C2 - 33844839
AN - SCOPUS:85104343624
SN - 0022-3395
VL - 107
SP - 284
EP - 288
JO - Journal of Parasitology
JF - Journal of Parasitology
IS - 2
ER -
